QGEN analyst estimates
QIAGEN (QGEN) analyst ratings, the average price target and its range, and every firm's latest call.
QGEN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 22, 2026 | Robert W. Baird | Qiagen price target raised to $52 from $50 at Baird | $52.00 |
| Sep 9, 2026 | UBS | Qiagen initiated with a Neutral at UBS | $47.00 |
| Aug 7, 2026 | Barclays | Qiagen price target raised to $40 from $38 at Barclays | $40.00 |
| Aug 7, 2026 | Stifel Nicolaus | Qiagen price target raised to $40 from $36 at Stifel | $40.00 |
| Aug 6, 2026 | Jefferies | Qiagen price target raised to $48 from $46 at Jefferies | $48.00 |
| Jul 14, 2026 | Berenberg Bank | Qiagen downgraded to Hold from Buy at Berenberg | $45.50 |
| Jun 25, 2026 | Kepler Capital | Qiagen initiated with a Hold at Kepler Cheuvreux | $38.60 |
| Jun 23, 2026 | Morgan Stanley | Qiagen upgraded to Overweight from Equal Weight at Morgan Stanley | $42.00 |
| May 18, 2026 | Stifel Nicolaus | Qiagen price target lowered to $36 from $50 at Stifel | $36.00 |
| Apr 30, 2026 | Deutsche Bank | Qiagen price target lowered to $43 from $54 at Deutsche Bank | $43.00 |
| Apr 29, 2026 | Robert W. Baird | Qiagen upgraded to Outperform from Neutral at Baird | $43.00 |
| Apr 29, 2026 | Barclays | Qiagen price target lowered to $38 from $44 at Barclays | $38.00 |
| Apr 14, 2026 | Barclays | Qiagen downgraded to Equal Weight from Overweight at Barclays | $44.00 |
| Feb 9, 2026 | UBS | Qiagen price target raised to $52 from $50 at UBS | $52.00 |
| Feb 6, 2026 | Robert W. Baird | Qiagen price target raised to $53 from $48.42 at Baird | $53.00 |
- 9 firms rate QGEN: 3 buy, 6 hold, 0 sell.
- The average price target is $44.14 from 8 analysts, from $38.60 to $52.00.
Updated 2026-11-02 17:52 UTC